IDEXX says Q2 2026 revenue rise is driven by double-digit growth in companion animal diagnostics recurring sales

Reuters2026/08/04 13:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IDEXX posted Q2 2026 revenue growth of about 10% reported, driven by 10.3% organic growth in CAG Diagnostics recurring revenue.
Performance reflected higher testing volumes despite a 1.3% decline in US same-store clinical visits; net price improvement ran about 4% globally.
Premium instrument placements totaled 5,265 units, including 1,602 inVue Dx analyzers; instrument revenue fell 20% organically on a tougher comparison.
Comparable operating margin rose 110 basis points to 35%, aided by recurring revenue mix, productivity, and favorable product costs; EPS was $4.27.
Full-year guidance increased to revenue of $4.7 billion-$4.75 billion, organic growth of 8.5%-9.7%, and EPS of $14.69-$14.94.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IDEXX says Q2 2026 revenue rise is driven by double-digit growth in companion animal diagnostics recurring sales

You may also like

Crypto prices